Gottlieb’s New Year’s Wish List: Risk Management Plans Out, Science In

The growing use of risk management plans to mitigate risk in the post-marketing setting presents "potential harm to patients and the practice of medicine," FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb said during a speech on drug safety at the Manhattan Institute in New York Nov. 13

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet